Gene Name		Sequences
iNOC	forward	GGCTGTCAGAGCCTCGTGGC
11105	reverse	CCCTTCCGAAGTTTCTGGCA
COY_{2}	forward	AACACAGCTACGAAAACC
COX2 -	reverse	CACAGTATGATGTAACAGT
	forward	GGCAGGTCTACTTTGGAGTCA
$IINF\alpha$	reverse	ACATTCGAGGCTCCAGTGAAT
II 1 <i>R</i>	forward	ATGGCAACTGTTCCTGAACTC
1L-1 <i>p</i>	reverse	CAGGACAGGTATAGATTCTTT
ПС	forward	GAGGATACCACTCCCAACAGA
1L0	reverse	AAGTGCATCATCGTTGTTCATA
Candle	forward	TTGTGATGGGTGTGAACCAC
Gupun	reverse	ACACATTGGGGGTAGGAACA

Table S1. List of the primer sets used in the study.

Table S2. List of the primary antibodies used in the study.

Name	Catalog no.	Company	Antigen	Host
Anti-iNOS	MAB9502	R&D systems	iNOS	Mouse
Anti-COX2	AF4198	R&D systems	COX2	Goat
Anti-p-ΙκΒ-α	sc-8404	Santa Cruz Biotechnology, Inc.	ΙκΒ-α	Mouse
Anti-IκB-α	sc-373893	Santa Cruz Biotechnology, Inc.	ΙκΒ-α	Mouse
Anti-NF-κB (p65)	BS1254	Bioworld Technology, Inc.	NF-ĸB (p65)	Rabbit
Anti-Histone H3	BS1405	Bioworld Technology, Inc.	Histone H3	Rabbit
Anti-p-p38	sc-166182	Santa Cruz Biotechnology, Inc.	p38	Mouse
Anti-p38	BS3567	Bioworld Technology, Inc.	p38	Rabbit
Anti-p-ERK1/2	sc-7383	Santa Cruz Biotechnology, Inc.	ERK	Mouse
Anti-ERK1/2	BS 6472	Bioworld Technology, Inc.	ERK	Rabbit
Anti-p-JNK	BS 4322	Bioworld Technology, Inc.	JNK	Rabbit
Anti-JNK	sc-7345	Santa Cruz Biotechnology, Inc.	JNK	Mouse
Anti- βactin	Sc-47778	Santa Cruz Biotechnology, Inc.	β-actin	Mouse

Table S3	. The X-ray	crystallographic	: information	of protein	and the	e center	of the g	rid box	and the
dimensio	n during do	ocking s imulat	ions using	; AutoDo	ock Vi	na.			

םו פרופ	Courses	Resolution	Co-crystallized	Grid box			
PDBID	Source		inhibitor	Center		Dimension	
5IKQ	Homo sapiens	2.41 Å	Meclofenamic Acid	x	27.34	x	25
				у	45.72	у	25
				z	19.61	Z	25
1CVU	Mus musculus	2.40 Å	Arachidonic Acid	x	28.37	x	25
				у	29.09	у	25
				z	40.76	Z	25

		Binding energy (kcal/mol)	Binding interactions				
PDB ID	Ligand name		Hydrogen bond interaction residue				
			Bond length (Å)			Trydrophobic bond interaction residue	
	Meclofenamic acid	-9.0	Ser530	3.13	Ala527, Gly526, Leu352, Leu531, Met522, Ser353, Trp387, Tyr 348, Tyr385, and Val349		
		-8.0	Arg222	3.31			
				3.14			
5IKQ			Asn382	3.08			
	ICSB		Thr206	2.77	Gln203, Gln289, His214, His386, His388, Lys211, Phe210, and Val291		
			Tyr385	2.71			
				3.01			
			Trp387	2.79			
1CVU	Arachidonic 7.9		L 011521	2 15	Ala527, Gly526, Leu352, Leu359, Leu531, Met113, Met522, Phe 381, Phe518,		
	acid	-7.9	Leubbi	5.15	Ser353, Ser530, Trp387, Tyr 355, Tyr385, Val166, Val349, and Val523		
	ICSB	-7.4	Ala199	2.80	- Ala 202 Cla202 Hig207 Hig214 Hig286 Hig288 Lau200 Lau201 and		
			Thr212	3.34	Aia 202, Giii203, 11is207, 11is214, 11is300, 11is300, Leu390, Leu391, aiu		
			Thr206	2.77	V d1447		
			Trp387	2.98			

Table S4. Binding energy and binding interactions of meclofenamic acid, arachidonic acid and ICSB docked against human and murine COX-2 protein.



Figure S1. Superposition of bound ligand for the validation of docking protocol. Superposition of the (**A**) best docked structure (green) and crystallographic structure for the human COX-2 protein and meclofenamic acid complex (red) (PDB accession no. 5IKQ) and (**B**) best docked structure (green) and crystallographic structure for the murin COX-2 protein and arachidonic acid complex (red) (PDB accession no. 1CVU).



Figure S2. Molecular docking analysis of arachidonic acid with X-ray crystallographic structure of human COX-2 protein (1CVU). Bonding interaction between original ligand (arachidonic acid) (**A** and **B**) human COX-2 protein (1CVU). The 3D and 2D binding conformation were visualized as diagrams using Discovery Studio Visualization version 4.5 and LigPlot viewer.



Figure S3. Molecular docking analysis meclofenamic acid with X-ray crystallographic structure of murine COX-2 protein (PDB: 5IKQ). Bonding interaction between original ligand (meclofenamic acid) (**A** and **B**) and murine COX-2 protein (PDB: 5IKQ). The 3D and 2D binding conformation were visualized as diagrams using Discovery Studio Visualization version 4.5 and LigPlot viewer.